|
1
|
Liu L, Wang D, Wong KS and Wang Y: Stroke
and stroke care in China, Huge burden, significant workload and a
national priority. Stroke. 42:3651–3654. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thrift AG, Dewey HM, Macdonell RA, McNeil
JJ and Donnan GA: Incidence of the major stroke subtypes, Initial
findings from the North East Melbourne stroke incidence study
(NEMESIS). Stroke. 32:1732–1738. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Flossmann E, Schulz UG and Rothwell PM:
Systematic review of methods and results of studies of the genetic
epidemiology of ischemic stroke. Stroke. 35:212–227. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schunkert H, König IR, Kathiresan S,
Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M,
Gieger C, et al: Large-scaleassociation analyses identifies 13 new
susceptibility loci for coronary artery disease. Nat Genet.
43:333–338. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Libby P: Inflammation in atherosclerosis.
Nature. 420:868–874. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dada N, Kim NW and Wolfert RL: Lp-PLA2: An
emerging biomarker of coronary heart disease. Expert Rev Mol Diagn.
2:17–22. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi Y, Zhang P, Zhang L, Osman H, Mohler
ER III, Macphee C, Zalewski A, Postle A and Wilensky : Role of
lipoprotein-associated phospholipase A2 in leukocyte activation and
inflammatory responses. Atherosclerosis. 191:54–62. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sutton BS, Crosslin DR, Shah SH, Nelson
SC, Bassil A, Hale AB, Haynes C, Goldschmidt-Clermont PJ, Vance JM,
Seo D, et al: Comprehensive genetic analysis of the platelet
activating factor acetylhydrolase (PLA2G7) gene and cardiovascular
disease in case-control and family datasets. Hum Mol Genet.
17:1318–1328. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ragoschke-Schumm A, Yilmaz U, Kostopoulos
P, et al: 'Stroke room': Diagnosis and treatment as a single
location for rapid intraarterial stroke treatment. Cerebrovasc Dis.
40:251–257. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adams HP Jr, Bendixen BH, Kappelle LJ,
Biller J, Love BB, Gordon DL and Marsh EE III: Classification of
subtype of acute ischemic stroke. Definitions for use in a
multicenter clinical trial. TOAST. Trial of Org 10172 in acute
stroke treatment. Stroke. 24:35–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li L, Qi L, Lv N, Gao Q, Cheng Y, Wei Y,
Ye J, Yan X and Dang A: Association between lipoprotein-associated
phospholipase A2 gene polymorphism and coronary artery disease in
the Chinese Han population. Ann Hum Genet. 75:605–611. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jang Y, Kim OY, Koh SJ, Chae JS, Ko YG,
Kim JY, Cho H, Jeong TS, Lee WS, Ordovas JM and Lee JH: The
Val279Phe variant of the lipoprotein-associated phospholipase A2
gene is associated with catalytic activities and cardiovascular
disease in Koreanmen. J Clin Endocrinol Metab. 91:3521–3527. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hiramoto M, Yoshida H, Imaizumi T,
Yoshimizu N and Satoh K: A mutation in plasma platelet-activating
factor acetylhydrolase (Val279->Phe) is a genetic risk factor
for stroke. Stroke. 28:2417–2420. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng GH, Xiong SQ, Chen HY, Mei LJ and
Wang T: Associations of platelet-activating factor acetylhydrolase
(PAFAH) gene polymorphisms with circulating PAF-AH levels and risk
of coronary heart diseaseor blood stasis syndrome in the Chinese
Han population. Mol Biol Rep. 41:7141–7151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosso C, Rosenbaum D, Pires C, Cherfils C,
Koujah N, Mestari F, Gillet E, Crozier S, Sahli-Amor M, Samson Y,
et al: Lipoprotein-associated phospholipase A2 during the
hyperacute stage of ischemic and hemorrhagic strokes. J Stroke
Cerebrovasc Dis. 23:277–282. 2014. View Article : Google Scholar
|
|
16
|
Tsimikas S, Willeit J, Knoflach M, Mayr M,
Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q and Kiechl
S: Lipoprotein-associated phospholipase A2 activity, ferritin
levels, metabolic syndrome and 10-year cardiovascular and
non-cardiovascular mortality, Results from the Bruneck study. Eur
Heart J. 30:107–115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Q, Hao Y, Mo X, Wang L, Lu X, Huang
J, Cao J, Li H and Gu D: PLA2G7 gene polymorphisms and coronary
heart disease risk, A meta-analysis. Thromb Res. 126:498–503. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zalewski A and Macphee C: Role of
lipoprotein-associated phospholipase A2 in atherosclerosis: Biology
epidemiology and possible therapeutic target. Arterioscler Thromb
Vasc Biol. 25:923–931. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Macphee CH, Nelson JJ and Zalewski A:
Lipoprotein-associated phospholipase A2 as a target of therapy.
Curr Opin Lipidol. 16:442–446. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vittos O, Toana B, Vittos A and Moldoveanu
E: Lipoprotein-associated phospholipase A2 (Lp-PLA2): A review of
its role and significance as a cardiovascular biomarker.
Biomarkers. 17:289–302. 2012. View Article : Google Scholar : PubMed/NCBI
|
